Acorda Therapeutics Inc (ACOR.O)

ACOR.O

About

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system.... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.82
Market Cap (Mil.):	$1,408.05
Shares Outstanding (Mil.):	40.57
Dividend:	--
Yield (%):	--

Financials

	ACOR.O	Industry	Sector
P/E (TTM):	9.66	34.05	33.02
EPS (TTM):	3.59	--	--
ROI:	37.79	-2.50	19.07
ROE:	47.80	-3.10	20.00

Latest News about ACOR.O

» More ACOR.O News

Competitors

	Price	Change
Biogen Idec Inc (BIIB.OQ)	$217.88	+2.67
Teva Pharmaceutical Industries Limited (TEVA.TA)	14,200.00₪	+70.00
Elan Corporation, plc (ELN.I)	€10.72	-0.05
Novartis AG (NOVN.VX)	CHF67.10	-0.20
BioMarin Pharmaceutical Inc. (BMRN.OQ)	$59.44	+3.65

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Trading Report for (ACOR). A detailed report, including free correlated market analysis, and updates. Provider: Stock Traders Daily	$58.00 Buy
The Investment Rate - a measure of investment demand. Provider: Stock Traders Daily	$495.00 Buy
Thomson Reuters Stock Report - ACORDA THERAPEUTICS, INC. (ACOR-O) Provider: Thomson Reuters Stock Report	$25.00 Buy
ACORDA THERAPTUTICS INC (ACOR) - REPORT FOR ACTIVE TRADERS Provider: Pechala's Reports	$25.00 Buy
ACORDA THERAPTUTICS INC (ACOR) 12-months forecast Provider: Pechala's Reports	$15.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.